[{"id":"91617f4c-9c7b-440c-8f75-457b27099289","acronym":"","url":"https://clinicaltrials.gov/study/NCT02802423","created_at":"2021-01-18T13:44:49.074Z","updated_at":"2025-02-25T16:30:52.764Z","phase":"Phase 1/2","brief_title":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","source_id_and_acronym":"NCT02802423","lead_sponsor":"BioLite, Inc.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • ABV-1501"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 08/28/2027","study_completion_date":" 08/28/2027","last_update_posted":"2025-02-07"}]